Operator's Information

Duk-Woo Park, MD

Country Korea (Republic of)
Specialty Interventional Cardiologist
  1. Escalation and De-Escalation Strategy for CHIP-PCI Patients: The TAILORED-CHIP Trial
  2. DAPT Duration in Complex PCI: Unsettled or Already Established Issues?
  3. PCI Is Enough. - When PCI Should Not Be Standard Treatment
  4. Optimizing Follow-up Strategies Post Complex PCI: Answers from the POST-PCI Trial
  5. Celebration of LM PCI: Joy in Growth, Journeying Towards 25 Years
  6. TAVI Procedure Plan and How to Achieve Successful Results
  7. Make It Simple : TAVR Antithrombotics
  8. Optimal Duration of Antiplatelet Therapy Following Left Main and Bifurcation PCI
  9. FATE-MAIN Trial
  10. TAILRORED-CHIP Trial
  11. Anticoagulation vs. Antiplatelet After TAVR: ADAPT-TAVR Trial
  12. Eagle's Eye View: How to Get Patients on a Statin Timely and Keep Them on It
  13. SAPIEN: Simpler and More Sophisticated (X4 and ALLIANCE)
  14. Insight from All Data of Left Main Revascularization (MAINCOMPARE, SYNTAX, PRECOMBAT, NOBLE, EXCEL)
  15. Edoxaban vs. DAPT for Valve Thrombosis and Cerebral Thromboembolism After TAVR: Deep-Dive into ADAPT-TAVR Trial
  16. Case 1. Left Main Disease
  17. DM and Triple Vessel Disease; Old Evidence and Next New Trials?
  18. My Approach to Left Main Coronary Disease - Master\'s Skill Secret
  19. LM Revascularization 2022: Guidelines and Concept Change
  20. Long-Term Valve Durability Issues and Optimal Decision-Making: TAVR or SAVR, Mechanical or Bioprosthetic?
  21. Key Message from the ADAPT-TAVR Trial: What We Learned?
  22. Leaflet Thrombosis, Is It Clinically Relevant?
  23. Racial Disparities in TAVR: Similarities and Differences
  24. Clinical Impact of Patient-Prosthesis Mismatch After TAVR
  25. Pragmatic Antithrombotic Strategies According to Bleeding and Ischemic Risk
  26. Two Road Diverged in a Cath Lab: PCI vs CABG in Complex PCI
  27. How to Optimize Sapien 3 Implantation for Future Management: FCA, Bicuspid, ViV, Low risk AS
  28. What Is Your Choice for Adherance Hypertensive Patients with Dyslipidemia?
  29. Escalation and De-Escalation Strategy for CHIP-PCI Patients: The Temporal Tuning in the TAILORED-CHIP Trial
  30. 10-Year Final Report of PRECOMBAT Trial: Deep-Dive
  31. My Challenging LM PCI Case of the Year
  32. East-Asian Paradox for Antithrombotics: Theory, Evidence and Next Strategy
  33. [Master\'s Keynote Lecture] Hand Down a Secret of Left Main PCI
  34. Antithrombotic and Antiplatelet Choice in Complex PCI
  35. Integrated Use of Imaging and Physiology in Left Main PCI
  36. Optimal Antithrombotics After TAVR
  37. Current Status of TAVR in Korea and US: TP-TAVR Registry
  38. TAVR Will Be a Standard Treatment for All Patients with Aortic Stenosis
  39. Balloon-Expandable SAPIEN 3 Valve
  40. Bifurcation PCI: Data, Evidence, and Guidelines
  41. Impact of Severe Coronary Artery Calcification on PCI Outcomes
  42. Optimal Antithrombotics After TAVR: Ongoing Trials
  43. OCT Versus IVUS for Guiding PCI: Current Evidences and Ongoing OCTIVUS Trial
  44. 10-Year Follow-Up of MAIN-COMPARE Registry and Substudies
  45. Anticoagulation for TAVR: GALILEO, and Yet It Moves.
  46. LM Bifurcation
  47. East-Asian Paradox: How to Optimize P2Y12 Inhibitors for Asians?
  48. How To Do Successful Registry Studies?
  49. Bifurcation PCI 2019: What Are Novel Changes for Technique or Concept?
  50. Highlighting 20 years of CV Protection with Lipitor
  51. PCI in Post-TAVR Patients: Beyond the Barrier
  52. Severe Coronary Calcification: Predictors, Managing Strategy, and Outcomes
  53. Integrated Use of FFR and IVUS in Non-LM Bifurcation PCI
  54. Clinical Impact of Periprocedural Myocardial Injury After TAVR
  55. Optimal Antithrombotic Therapy and Ongoing Clinical Trials
  56. Mainstream of TAVR: Minimalist Approach
  57. Permanent Pacemaker and Para-valvular Leakage: How to Avoid?
  58. Minimalist TAVR with Edwards SAPIEN 3 Valve
  59. Time to Consider Different P2Y12 Strategy for Complex PCI/CHIP Patients: From OPTIMA to TAILORED-PCI Trial
  60. Ture Distal Left Main PCI (Medina 1,1,1 or 1,0,1) Contemporary Strategy: Provisional vs. Complex
  61. Metallic DES Are All Equivalent!
  62. TAVR in Asia: Current Challenges and Future Direction
  63. Comparative Outcomes of Contemporary DES in Real-World: Is There Difference?
  64. EBC-MAIN Like Analysis Using the Largest Real-World Left Main Database
  65. Valve Thrombosis, Durability and Ongoing Antithrombotic Trials for TAVR
  66. OPTIMA Trial: P2Y12 Dose Adjustment for East-Asian ACS Patients
  67. Top 10 Tips on Bifurcation PCI
  68. Heavily Calcified Lesion: Rotational Atherectomy and Others
  69. Keynote Lecture on Bifurcation PCI: Expert\'s Concept and Technique
  70. TAVR - Moving to Lower Risk: STS or Age Per Se?
  71. Standard vs. Minimalist TAVR: When and How to Change?
  72. [Taped Case] TAVR with Sapien
  73. CTEPH; Diagnosis & Treatment
  74. All Contemporary DES Comparison; Data from Real-World Registry (IRIS-DES)
  75. Trends and Outcomes of Non-LM and LM Bifurcation PCI
  76. How Do I Choose Sapien 3, Evolut R or Lotus in My Practice?
  77. Long-Term Durability Issue of TAVR; Uncertainty or Would Be OK
  78. Contemporary Bifurcation PCI; How Advance over Time?
  79. Generalizability of EXCEL and NOBLE; Comparison with IRIS-MAIN Registry
  80. Where to Go? - Comparative Analysis: BMS, DES vs. BVS / - The Next Step: BVS in Challenging Lesions
  81. Can Different DES Make a Different Outcome?
  82. Future in Transcatheter Heart Valve Treatment
  83. SYNERGY : Latest Experience from Korea
  84. Growing Importance of Evidence in the Management of High CV Risk Patients
  85. How Much Promising BRS in Real-Practice PCI?; Updated Real-World Experience and Registry Data
  86. Bifurcation PCI Summary; Technique or Concept?
  87. BRS in Left Main PCI: Clinical Data and Experience
  88. DES Thrombosis and Restenosis: Still Problematic in Current Real-World with Updated DES
  89. Effect of Statin Therapy on Cardiovascular Outcome in Dyslipidemic Patients with CKD
  90. BVS: They Will Replace Metallic DES?
  91. Comparative Outcomes of New-Generation DES: IRIS-DES
  92. Can BVS Replace the Metal Stent?: Current Status and Future Perspective
  93. Shifting the Paradigm for Lipid Management: Pathways in Achieving Improved ASCVD Outcomes
  94. RDN; Indications & Evidence and Future
  95. Use of a Point-of-Care Platelet Function Assay to Improve the Prediction of Atherothrombotic Events after DES Implantation: ASAN-VerifyNow Registry
  96. Long-Term Outcomes After Stenting Versus Coronary Artery Bypass Grafting for Unprotected Left Main Coronary Artery Disease: 10-Year Results of Bare-Metal Stents and 5-Year Results of Drug-Eluting Stents From the ASAN–MAIN (ASAN Medical Center–Left MAIN Revascularization) Registry
  97. AMC Experience of the Intervention for the Structural Heart Disease
  98. Early DES - What Did We Learn - Updates from the ZEST Trial
  99. Alternative and Next Antiplatelet Therapy Beyond ADP Blocker
  100. Seeing Is Believing. IVUS Is A Mandatory in All Patients!
  101. DES vs. CABG for Multivessel Disease: Same or Different Interpretation from Registry to RCT
  102. Use of VH-Findings as Surrogate Marker for Anti-Atherosclerotic Drug
  103. Wrapping Up Current Clinical Trials and Future Study Program
  104. VH AMC Clinical Experience
  105. Meta-Analysis of 3,900 Patients with Left Main Disease Intervention (BMS vs DES vs CABG)
  106. Impact of DES on Diabetes Mellitus in Long Coronary Lesion
Conference Slides
Category